Johnson & Johnson (NYSE:JNJ) Shares Acquired by Silverlake Wealth Management LLC

Silverlake Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,449 shares of the company’s stock after purchasing an additional 302 shares during the period. Johnson & Johnson comprises about 2.0% of Silverlake Wealth Management LLC’s portfolio, making the stock its 5th largest holding. Silverlake Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,868,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Naviter Wealth LLC lifted its position in shares of Johnson & Johnson by 43.8% in the first quarter. Naviter Wealth LLC now owns 20,281 shares of the company’s stock valued at $3,208,000 after acquiring an additional 6,174 shares in the last quarter. Quattro Financial Advisors LLC lifted its holdings in Johnson & Johnson by 27,610.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 43,506 shares of the company’s stock valued at $6,882,000 after purchasing an additional 43,349 shares in the last quarter. MV Capital Management Inc. boosted its stake in Johnson & Johnson by 5.3% during the 1st quarter. MV Capital Management Inc. now owns 18,942 shares of the company’s stock worth $2,996,000 after purchasing an additional 947 shares during the last quarter. Woodmont Investment Counsel LLC raised its position in shares of Johnson & Johnson by 2.9% in the first quarter. Woodmont Investment Counsel LLC now owns 81,823 shares of the company’s stock valued at $12,944,000 after buying an additional 2,318 shares during the last quarter. Finally, Exchange Capital Management Inc. lifted its stake in shares of Johnson & Johnson by 32.2% in the first quarter. Exchange Capital Management Inc. now owns 16,052 shares of the company’s stock worth $2,539,000 after buying an additional 3,912 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $145.62 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a market cap of $350.46 billion, a P/E ratio of 9.08, a PEG ratio of 2.43 and a beta of 0.52. The firm’s 50 day moving average price is $148.02 and its 200 day moving average price is $153.91.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm earned $2.68 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s payout ratio is currently 30.92%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. The Goldman Sachs Group started coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.